If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

A study published in Foresight demonstrates that Kognitic's neural network model significantly outperforms traditional methods in predicting primary completion dates (PCD) for clinical trials, ...

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics ...

MorganFranklin Consulting's cybersecurity practice announced that it has completed a private equity backed management buyout from the broader MorganFranklin Consulting organization to become a ...

And yet, data science is now poised to usher in a level and acceleration of progress that even life sciences have never ...